This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
09 July 2010
In the version of this article initially published, in Table 1, the Emergent BioSolutions’ anthrax countermeasures in development listed AV-7909 as being in phase 2 under a $447.6 million BARDA contract; AV-7909 is in phase 1 and the BARDA contract is for $29.7 million. AIGIV is in phase 1/3, not phase 1/2. Finally, a third product was omitted; anthrax monoclonal is in preclinical testing under a $24 million BARDA contract. The $447.6 million BARDA contract was for procurement and product enhancements on BioThrax. Also, on p.188, column 2, line 7, the vaccine requires five injections, not six as originally stated. The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shaffer, C. US biodefense contracts continue to lure biotechs. Nat Biotechnol 28, 187–188 (2010). https://doi.org/10.1038/nbt0310-187
Issue Date:
DOI: https://doi.org/10.1038/nbt0310-187
This article is cited by
-
Fresh from the biotech pipeline—2016
Nature Biotechnology (2017)
-
Erratum: US biodefense contracts continue to lure biotechs
Nature Biotechnology (2010)